JPRN-UMIN000052594
Recruiting
未知
Expert Opinion on the Proper Use of Teduglutide as Treatment for Short Bowel Syndrome in Adult Patients - Expert Opinion on the Proper Use of Teduglutide as Treatment for Short Bowel Syndrome in Adult Patients
Conditionsshort bowel syndrome
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- short bowel syndrome
- Sponsor
- Takeda Pharmaceutical Company Limited
- Enrollment
- 10
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Not applicable
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A Study of the Safety and Efficacy of Teduglutide in Subjects with Parenteral Nutrition-Dependant Short Bowel Syndrome Who Completed Protocol CL0600-004 - N/AEUCTR2004-000439-27-DKPS Allelix Corporation80
Recruiting
Not Applicable
Safety and Effectiveness of teduglutide (Revestive ®) treatment in paediatric patients with chronic intestinal failure due to short bowel syndrome – an observational studyK91.2Postsurgical malabsorption, not elsewhere classifiedDRKS00021006Klinik für Kinder- und JugendmedizinUniversitätsklinikum Ulm40
Active, not recruiting
Not Applicable
A study of the Efficacy and Safety of Teduglutide in subjects with Parenteral Nutritional Dependant Short Bowel Syndrome - N/AEUCTR2004-000438-35-DKPS Allelix Corporation125
Completed
Phase 3
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel SyndromeShort Bowel SyndromeNCT00081458Shire84
Completed
Not Applicable
Safety and efficacy of dulaglutide therapy for the inpatient management of general medicine patients with type 2 diabetesType 2 diabetesJPRN-UMIN000025006Ichinomiyanishi hospital40